Please try another search
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
| Name | Age | Since | Title |
|---|---|---|---|
| Carl H. June | 69 | 2017 | Member of Scientific Advisory Board |
| Jiny Kim | 46 | 2022 | Independent Director |
| Peter Wearden | - | - | Member of Cardiac Surgery Advisory Board |
| Phillip P. Chan | 53 | 2008 | CEO & Director |
| Mitchell Cohen | - | - | Member of Trauma Advisory Board |
| Ernest E. Moore | - | 2013 | Member of Trauma Advisory Board |
| Michael G. Bator | 59 | 2015 | Independent Chairman of the Board |
| Craig R. Smith | - | - | Member of Cardiac Surgery Advisory Board |
| Joseph Zwischenberger | - | 2014 | Chairman of Cardiac Surgery Advisory Board |
| Claudio Ronco | - | - | Member of Critical Care Advisory Board |
| Alan D. Sobel | 62 | 2014 | Independent Director |
| Robert H. Bartlett | 84 | 2009 | Co-Chairman of Cardiac Surgery Advisory Board & Consultant |
| Edward R. Jones | 75 | 2007 | Independent Director |
| Ronald V. Maier | - | 2013 | Chairman of the Trauma Advisory Board |
| Joseph E. Parrillo | - | - | Member of Critical Care Advisory Board |
| Jonathan William Haft | - | 2014 | Member of Cardiac Surgery Advisory Board |
| Nicholas Smedira | - | 2014 | Member of Cardiac Surgery Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
